Our results suggest that targeted therapies aimed at decreasing the levels of TRAIL-R2 in primary breast carcinomas and/or circulating tumor cells may represent a promising therapeutic strategy for reducing the risk of breast cancer patients to relapse with bone metastases. Here, TNFRSF10B is linked to breast carcinoma.